Successful treatment of EGFR-mutated non-small cell lung cancer with reduced-dose gefitinib: A case report

Epidermal growth factor receptor (EGFR) mutation is a favorable prognostic factor of non-small cell lung cancer (NSCLC). In the majority of patients with EGFR mutations, clinical benefits of EGFR-tyrosine kinase inhibitors (TKIs) have been reported. One of the TKIs, gefitinib, appears to be less tox...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Exp Ther Med
Asıl Yazarlar: WATANABE, HIROKO, TAMURA, TOMOHIRO, KAGOHASHI, KATSUNORI, TAKAYASHIKI, NORIO, KURISHIMA, KOICHI, SATOH, HIROAKI, HIZAWA, NOBUYUKI
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: D.A. Spandidos 2015
Konular:
Articles
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4487036/
https://ncbi.nlm.nih.gov/pubmed/26170967
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/etm.2015.2499
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller